Respiratory Tract Infection Treatment Market Size Report | 2031

The respiratory tract infection treatment market size is expected to reach US$ 69.13 billion by 2031 from US$ 43.6 billion in 2023; it is anticipated to register a CAGR of 5.93% during 2023–2031.

Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. The global respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players. Key factors driving the market growth include the rising prevalence of respiratory infections globally, increasing awareness related to respiratory tract infections and various therapeutics related to respiratory tract infection, and increasing number of clinical trials related to respiratory tract infection treatment. However, the lack of research focused on respiratory therapeutics and adverse effects related to respiratory infection drugs hinders market growth. Further, the advent of antiviral treatment is expected to bring new global respiratory tract infection treatment market trends in the coming years.

Growth Drivers and Restraints:

Rising Demand for Respiratory Disease Diagnosis Among Elderly Population

As the elderly population has grown globally, the demand for the diagnosis of respiratory diseases is anticipated to increase in the coming years. For instance, according to an article published in the British Journal of Pharmacology in November 2021, ~1% of the UK population is diagnosed with community-acquired pneumonia (CAP) annually. Approximately 70% of cases occur in those aged over 65, and the 30-day mortality is approximately 20% in this age group. Thus, the rise in the aging population and increase in the incidence of diseases such as CAP is expected to propel the demand for respiratory disease treatments, boosting the overall market growth.

Continuous research and development in this field has resulted in various diagnostic tests and procedures that will positively affect the growth of the market in the coming years. Innovative diagnostic methods are expected to offer good opportunities for market development during the forecast period. However,  the scarcity of research studies and adverse reactions related to respiratory tract infection drugs is expected to limit the global respiratory tract infection treatment market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Respiratory Tract Infection Treatment Market: Strategic Insights

Market Size Value in	US$ 43.6 billion in 2023
Market Size Value by	US$ 69.13 billion by 2031
Growth rate	CAGR of 5.93% from 2023 to 2031
Forecast Period	2023-2031
Base Year	2023

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The global respiratory tract infection treatment market analysis has been carried out by considering the following segments: drug disease indication, route of administration, age group, and distribution channel. Based on drugs, the market is differentiated into antibiotics, NSAIDs, cough suppressants, nasal decongestants, and others. By disease indication, the global respiratory tract infection treatment market is segmented into upper respiratory tract infection and lower respiratory tract infection. In terms of route of administration, the market is differentiated into oral and parenteral. On the basis of age group, the market is classified into pediatric and adult. Based on distribution channel, the global respiratory tract infection treatment market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

Segmental Analysis:

In terms of drug, the antibiotics segment held the largest global respiratory tract infection treatment market share in 2023. The segment is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens. Antibiotics target and eliminate these harmful bacteria, reducing inflammation and promoting faster recovery. Commonly prescribed antibiotics for respiratory tract infections include penicillins, cephalosporins, macrolides, fluoroquinolones, and tetracyclines, and each of these has unique action mechanisms and bacterial targets.

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others. Conditions such as pneumonia, bronchitis, and bronchiolitis, which typically exhibit symptoms such as productive cough, chest discomfort, shortness of breath, and fever, are categorized under the spectrum of LRTIs. Pneumonia, a severe LRTI, involves inflammation and infection of the lung tissue, leading to pulmonary consolidation (some areas of the lung or the complete organ) and impaired gas exchange.

By route of administration, the oral segment held a larger share of the global respiratory tract infection treatment market; the segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections. In addition to antibiotics, oral corticosteroids may reduce inflammation in severe asthma or chronic obstructive pulmonary disorder (COPD) exacerbations. Oral antiviral medications such as oseltamivir are utilized for treating viral respiratory infections such as influenza. The common advantages of the oral route include easy administration, patient compliance, and systemic drug distribution.

In terms of age group, the adult segment held a larger share of the global respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. Factors such as the awareness related to the importance of early diagnosis and treatment of respiratory infections in children and advancements in respiratory devices used for treatment are leading to the development of new and more effective treatment options. Moreover, the growing focus on preventive healthcare is contributing to the growth of the market for the pediatric segment.

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications. These pharmacies are responsible for sourcing, storing, and dispensing antibiotics, antivirals, corticosteroids, and other respiratory infection treatments, as well as ensuring their safe and timely delivery to inpatient and outpatient settings in hospitals.

Respiratory Tract Infection Treatment Market Report Scope

Regional Analysis:

The growing awareness among the population about the importance of early diagnosis and treatment of respiratory infections is likely to contribute to the global respiratory tract infection treatment market growth in the coming years. The market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America. North America held the largest global respiratory tract infection treatment market share in 2023. The market in North America is experiencing significant growth owing to the elevated prevalence of respiratory tract infections in the country. Factors such as air pollution, smoking, and crowded living conditions contribute to the high incidence of respiratory infections in the country. Increase in the prevalence of respiratory infections, a rise in awareness about healthcare, and favorable initiatives by the government are driving the global respiratory tract infection treatment market growth.

Competitive Landscape and Key Companies:

The global respiratory tract infection treatment market forecast can help stakeholders plan their growth strategies. Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Merck & Co., Cipla are among the prominent players profiled in the global respiratory tract infection treatment market report. These companies focus on various strategies (including both organic and inorganic) to meet the burgeoning consumer demand and expand their product range in specialty portfolios. The major strategies adopted by the companies in the market include new technology launches, existing product developments, and geographic expansions.